Skip to main content

Relpax and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Relpax (eletriptan).

Major

Eletriptan High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Major Potential Hazard, High plausibility

5-HT1 agonists - CAD risk factors

The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.

References

  1. Willett F, Curzen N, Adams J, Armitage M (1992) "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ, 304, p. 1415
  2. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH (1993) "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ, 307, p. 1185
  3. Curtin T, Brooks AP, Roberts JA (1992) "Cardiorespiratory distress after sumatriptan given by injection." BMJ, 305, d713-4
  4. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) "Transmural myocardial infarction with sumatriptan." Lancet, 341, p. 861-2
  5. MacLean MR, Smith GC, Templeton AG (1993) "Adverse reactions associated with sumatriptan." Lancet, 341, p. 1092
  6. Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ (1994) "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet, 343, p. 1105-6
  7. (2001) "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome
  8. Plosker GL, Mctavish D (1994) "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs, 47, p. 622-51
  9. Boyd IW, Rohan AP (1994) "Sumatriptan-induced chest pain." Lancet, 344, p. 1704-5
  10. Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC (1994) "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol, 47, p. 305-9
  11. Kelly KM (1995) "Cardiac arrest following use of sumatriptan." Neurology, 45, p. 1211-3
  12. Mueller L, Gallagher RM, Ciervo CA (1996) "Vasospasm-induced myocardial infarction with sumatriptan." Headache, 36, p. 329-31
  13. Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD (1996) "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology, 47, p. 46-51
  14. Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD (1996) "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia, 16, p. 554-9
  15. (2001) "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals
  16. (2001) "Product Information. Amerge (naratriptan)." Glaxo Wellcome
  17. (2001) "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc
  18. Dulli DA (1999) "Naratriptan: an alternative for migraine." Ann Pharmacotherapy, 33, p. 704-11
  19. Dooley M, Faulds D (1999) "Rizatriptan - A review of its efficacy in the management of migraine." Drugs, 58, p. 699-723
  20. Morgan DR, Trimble M, McVeigh GE (2000) "Atrial fibrillation associated with sumatriptan." Br Med J, 321, p. 275
  21. (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
  22. (2001) "Product Information. Frova (frovatriptan)." Endo Laboratories LLC
  23. (2003) "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals
View all 23 references
Major

Eletriptan Obesity

Major Potential Hazard, High plausibility

5-HT1 agonists - CAD risk factors

The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.

References

  1. Willett F, Curzen N, Adams J, Armitage M (1992) "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ, 304, p. 1415
  2. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH (1993) "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ, 307, p. 1185
  3. Curtin T, Brooks AP, Roberts JA (1992) "Cardiorespiratory distress after sumatriptan given by injection." BMJ, 305, d713-4
  4. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) "Transmural myocardial infarction with sumatriptan." Lancet, 341, p. 861-2
  5. MacLean MR, Smith GC, Templeton AG (1993) "Adverse reactions associated with sumatriptan." Lancet, 341, p. 1092
  6. Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ (1994) "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet, 343, p. 1105-6
  7. (2001) "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome
  8. Plosker GL, Mctavish D (1994) "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs, 47, p. 622-51
  9. Boyd IW, Rohan AP (1994) "Sumatriptan-induced chest pain." Lancet, 344, p. 1704-5
  10. Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC (1994) "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol, 47, p. 305-9
  11. Kelly KM (1995) "Cardiac arrest following use of sumatriptan." Neurology, 45, p. 1211-3
  12. Mueller L, Gallagher RM, Ciervo CA (1996) "Vasospasm-induced myocardial infarction with sumatriptan." Headache, 36, p. 329-31
  13. Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD (1996) "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology, 47, p. 46-51
  14. Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD (1996) "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia, 16, p. 554-9
  15. (2001) "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals
  16. (2001) "Product Information. Amerge (naratriptan)." Glaxo Wellcome
  17. (2001) "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc
  18. Dulli DA (1999) "Naratriptan: an alternative for migraine." Ann Pharmacotherapy, 33, p. 704-11
  19. Dooley M, Faulds D (1999) "Rizatriptan - A review of its efficacy in the management of migraine." Drugs, 58, p. 699-723
  20. Morgan DR, Trimble M, McVeigh GE (2000) "Atrial fibrillation associated with sumatriptan." Br Med J, 321, p. 275
  21. (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
  22. (2001) "Product Information. Frova (frovatriptan)." Endo Laboratories LLC
  23. (2003) "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals
View all 23 references

Relpax drug interactions

There are 216 drug interactions with Relpax (eletriptan).

Relpax disease interactions

There are 3 disease interactions with Relpax (eletriptan) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer